Casma Therapeutics to Present at the Keystone Symposia on Tumor Metabolism

February 13, 2024

CAMBRIDGE, Mass., February 12, 2024Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Leon Murphy, Ph.D., Chief Scientific Officer, will present at the Keystone Meeting on Tumor Metabolism in Banff, Alberta, Canada, in the “Targeting Metabolism” Section. The title of Dr. Murphy’s talk is “Targeting Autophagy.” The presentation will take place on Wednesday, February 14, 2024.  Dr. Murphy will also participate in the Career Roundtable on Tuesday, February 13, 2024.

About Casma Therapeutics

Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to initiate new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The autophagy machinery focuses on larger and more complex disease targets, such as organelles, protein aggregates, and large signaling complexes, and directs these targets to the lysosome for elimination. Through selective degradation of disease targets, Casma expects to arrest or reverse the progression of disease in multiple oncology, inflammation, neurodegeneration, and metabolic disorders.


Contact for Investors and Media

Courteney Backstrom
Casma Therapeutics, Inc.


Back to news & media

Keep reading: